Table 1.
Base Case |
Low | High | Source | |
---|---|---|---|---|
Population Distribution (true condition) | ||||
No/Mild Fibrosis | 69% | 67% | 71% | Poynard 200412 |
Moderate/High Fibrosis | 31% | 33% | 29% | Poynard 200412 |
Fibrosure Test Characteristics | ||||
Probabilities for patients with no/mild fibrosis | ||||
Test positive | 13% | 11% | 15% | Poynard et al 200412 |
Test indeterminate | 19% | 17% | 21% | Poynard et al 200412 |
Test negative | 68% | 64% | 72% | Poynard et al 200412 |
Probabilities for patients with moderate/severe fibrosis | ||||
Test positive | 56% | 54% | 58% | Poynard et al 200412 |
Test indeterminate | 28% | 26% | 30% | Poynard et al 200412 |
Test negative | 16% | 12% | 20% | Poynard et al 200412 |
Fibrospect II Characteristics | ||||
Probabilities for patients with no/mild fibrosis | ||||
Test positive | 29% | 21% | 36% | Prometheus Labs13 |
Test indeterminate | 0% | - | - | |
Test negative | 71% | 67% | 75% | Prometheus Labs13 |
Probabilities for patients with moderate/severe fibrosis | ||||
Test positive | 81% | 60% | 100% | Prometheus Labs13 |
Test indeterminate | 0% | - | - | |
Test negative | 19% | 15% | 23% | Prometheus Labs13 |
Fibroscan Test Characteristics | ||||
Probabilities for patients with no/mild fibrosis | ||||
Test positive | 11% | 8% | 14% | Castera et al.14 |
Test indeterminate | 0% | - | - | |
Test negative | 89% | 85% | 93% | Castera et al.14 |
Probabilities for patients with moderate/severe fibrosis | ||||
Test positive | 67% | 50% | 84% | Castera et al.14 |
Test indeterminate | 0% | - | - | |
Test negative | 33% | 29% | 37% | Castera et al.14 |
Costs* | ||||
Fibrosure Test | $215 | $161 | $269 | Labcorp personal communication 4/01/06 |
Liver Biopsy | $1,255 | $941 | $1,569 | Wong et al, 199823 |
Fibrospect II | $350 | $263 | $438 | Botts et al, 200524 |
Fibroscan | $131 | $98 | $164 | CEDIT, 200425 |
Adjusted to 2005 US dollars using medical care component of Consumer Price Index